Jessica J. Tao

发表

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

Borivoj Vojnovic, Dejan Juric, Charles M. Perou, 2014, Science Signaling.

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

Michael G. Kharas, A. Bergamaschi, S. Chandarlapaty, 2015, Science Translational Medicine.

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling

M. Barbacid, N. Rosen, R. Yaeger, 2018, Nature Medicine.

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

D. Hyman, D. Rasco, K. Cadoo, 2019, Clinical Cancer Research.

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.

David M Hyman, Alison M Schram, A. Schram, 2018, Annual review of medicine.

ALK Fusions in Renal Cell Carcinoma: Response to Entrectinib.

H. Al-Ahmadie, M. Arcila, Chung-Han Lee, 2018, JCO precision oncology.

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer

N. Rosen, Manway Liu, J. Baselga, 2013, Science Translational Medicine.

Elkabets-Mutant Breast Cancer PIK 3 CA Inhibitors in α mTORC 1 Inhibition Is Required for Sensitivity to PI 3 K p 110

Manway Liu, J. Baselga, M. Mino‐Kenudson, 2013 .

High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing.

W. Linehan, W. Linehan, K. Pacak, 2006, The Journal of clinical endocrinology and metabolism.

Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.

Jean L Wright, A. Wolff, L. Jacobs, 2020, JCO oncology practice.

Long term side effects of adjuvant chemotherapy in patients with early breast cancer.

A. Wolff, K. Visvanathan, J. Tao, 2015, Breast.

PI3K pathway inhibitors: better not left alone.

M. Scaltriti, B. Markman, J. Tao, 2012, Current pharmaceutical design.

Erratum for the research article: mTORC1 inhibition is required forsensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.3005747)

Manway Liu, J. Baselga, M. Mino‐Kenudson, 2018 .

Demonstrating the impact of POLST forms on hospital care requires information not contained in state registries

D. Needham, Anirudh Rao, J. Tao, 2019, PloS one.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.

Sunil Sharma, F. Janku, D. Hong, 2018 .